BridgeMD
New treatment option for Bronchiectasis Adult
Official title A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
ClinicalTrials.gov ID: NCT06931002
What this study is testing
What is Rhinovirus A-16 Infection?
Rhinovirus A-16 Infection is an investigational medicine, given as an once-daily, being studied as a potential treatment for bronchiectasis adult.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65. Healthy volunteers may be eligible.
You may be able to join if
- For healthy volunteers: 1) Age 18 to 65 years.
- For bronchiectasis study people:
- Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .
- For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.
You likely can't join if
- For healthy volunteers and bronchiectasis study people:
- Any medical co-morbidity impacting the study in the opinion of the medical team
- Current smoking history within last 12 months or ex smoking history \>5 pack years
- Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)
- Close contact with infants or elderly individuals either at home or workplace
- Pregnancy or breastfeeding
See the full eligibility criteria
- For healthy volunteers: 1) Age 18 to 65 years.
- For bronchiectasis study people:
- Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .
- For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.
- For healthy volunteers and bronchiectasis study people:
- Any medical co-morbidity impacting the study in the opinion of the medical team
- Current smoking history within last 12 months or ex smoking history \>5 pack years
- Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)
- Close contact with infants or elderly individuals either at home or workplace
- Pregnancy or breastfeeding
- For bronchiectasis study people: 1) Individuals with bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 2) Individuals with...
The study team makes the final eligibility decision.
Where it's taking place
- London, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.